We are live on ! Find out more
APVO icon

Aptevo Therapeutics
APVO

1 hedge funds and large institutions have $89.7M invested in Aptevo Therapeutics in 2021 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 1 → 1 (0)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more ownership

Funds ownership: 0% → 0% (0%)

16% less capital invested

Capital invested by funds: $107M → $89.7M (-$17M)

Holders
1
Holders Change
–
Holders Change %
0%
% of All Funds
0.02%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
–
Increased
–
Reduced
–
Closed
–
Calls
$19.6M
Puts
–
Net Calls
+$19.6M
Net Calls Change
+$19.6M

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
PVI
Pura Vida Investments
New York
-$301K
2
SFI
Susquehanna Fundamental Investments
Pennsylvania
-$235K
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$231K
4
Millennium Management
Millennium Management
New York
-$228K
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$202K
Name Holding Trade Value Shares
Change 		Change in
Stake
TCM
1
Tang Capital Management
California
$53.7M – – –
RI
2
RTW Investments
New York
$8.59M – – –
Renaissance Technologies
3
Renaissance Technologies
New York
$6.38M – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$4M – – –
Alyeska Investment Group
5
Alyeska Investment Group
Illinois
$2.64M – – –
Balyasny Asset Management
6
Balyasny Asset Management
Illinois
$1.87M – – –
BlackRock
7
BlackRock
New York
$1.76M – – –
GTC
8
Ghost Tree Capital
New York
$1.53M – – –
AFM
9
Anson Funds Management
Texas
$1.48M – – –
Two Sigma Investments
10
Two Sigma Investments
New York
$1.21M – – –
SCM
11
Stonepine Capital Management
Oregon
$1.18M – – –
Geode Capital Management
12
Geode Capital Management
Massachusetts
$1.09M – – –
Two Sigma Advisers
13
Two Sigma Advisers
New York
$928K – – –
Bank of Montreal
14
Bank of Montreal
Ontario, Canada
$674K – – –
BFM
15
Boothbay Fund Management
New York
$447K – – –
DTL
16
Dynamic Technology Lab
Singapore
$428K – – –
QI
17
QS Investors
New York
$348K – – –
Bank of New York Mellon
18
Bank of New York Mellon
New York
$305K – – –
SSA
19
Schonfeld Strategic Advisors
New York
$296K – – –
Northern Trust
20
Northern Trust
Illinois
$255K – – –
Marshall Wace
21
Marshall Wace
United Kingdom
$244K – – –
JC
22
JBF Capital
Colorado
$119K – – –
Morgan Stanley
23
Morgan Stanley
New York
$97K – – –
Bank of America
24
Bank of America
North Carolina
$56K – – –
Wells Fargo
25
Wells Fargo
California
$47K – – –
1
2

APVO Hedge Fund Activity: Q1 2021 in Review

1 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Aptevo Therapeutics (APVO) for Q1 2021, worth a combined $89.7M — down 16% from $107M a quarter earlier.

Fund positioning in APVO was balanced in Q1 2021: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

The largest seller was Pura Vida Investments, cutting an estimated $301K.

  • 1 institutional investor held Aptevo Therapeutics (APVO) as of Q1 2021, unchanged from Q4 2020.
  • Funds reported $89.7M of Aptevo Therapeutics stock for Q1 2021, down 16% quarter-over-quarter.
  • 0 funds opened new Aptevo Therapeutics positions in Q1 2021 and 0 closed out.
  • The largest Aptevo Therapeutics seller in Q1 2021 was Pura Vida Investments, an estimated $301K sold.

Based on aggregated 13F filings for Q1 2021.